FSD Phar­ma scoops GW Phar­ma ex­ec to guide cannabi­noid de­vel­op­ment; Zealand Phar­ma is look­ing for a new CEO

→ Just a month af­ter GW Phar­ma­ceu­ti­cals launched its pi­o­neer­ing cannabis-de­rived drug in the US, its head of mar­ket­ing has jumped to lead FSD Phar­ma, a Cana­di­an biotech that wants to fol­low GW’s foot­steps. Ru­pert Haynes will set up his own CEO of­fice in the UK, where he’s been based. FSD’s pipeline will con­sist large­ly of pain, mi­graine and CNS treat­ments like Tourette syn­drome, ob­tained through a re­cent ac­qui­si­tion of Is­rael’s Ther­a­pix.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER